---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-110374"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:10:29.138798+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tivic Health receives two INDs for Entolimod from Statera for ARS and advanced cancers

## Summary
- Completed transfer of two INDs from Statera Biopharma for lead candidate Entolimod.
- INDs cover acute radiation syndrome (ARS-H and ARS-GI sub-syndromes) and advanced cancers.
- Enables formal FDA engagement on regulatory pathway for ARS; near-term focus on ARS as first indication.
- Also enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-treatment conditions.

## SEC filing metadata
- accession: 0000950170-25-110374
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025110374/0000950170-25-110374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025110374/tivc-20250820.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-110374
- JSON: https://secwatch.observer/filing/0000950170-25-110374.json
- Plain text: https://secwatch.observer/filing/0000950170-25-110374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.